Ketamine's Antidepressant Secret May Involve a Neuropeptide Receptor Called VPAC2 | Research

The takeaway

By mapping which proteins the brain makes after ketamine treatment, researchers discovered that activating the VPAC2 receptor — which responds to the neuropeptide VIP — can produce antidepressant effects on its own.

VPAC2 agonism = antidepressant
Directly activating the VIP neuropeptide receptor VPAC2 was sufficient to drive antidepressant-like responses in mice — independent of ketamine

What the researchers found

Using ribosome profiling (RiboSeq) to capture the complete set of actively translated proteins in the medial prefrontal cortex after antidepressant-dose ketamine, researchers identified VPAC2 — the receptor for the neuropeptide vasoactive intestinal peptide (VIP) — as a novel target for antidepressant action.

VPAC2 expression in the prefrontal cortex was found to be limited to somatostatin-positive inhibitory neurons. When a VPAC2 agonist was administered in vivo, it bidirectionally modulated pyramidal neuron activity and disrupted coordinated neural activity patterns. Critically, VPAC2 agonism alone was sufficient to drive an antidepressant response in mice, validating this neuropeptide receptor as a potential drug target independent of ketamine itself.

Why it matters

Depression affects hundreds of millions of people worldwide, and many patients don't respond to standard antidepressants. Ketamine works fast but has practical limitations including its dissociative effects. Identifying that a specific neuropeptide receptor — VPAC2 — can independently produce antidepressant effects opens the door to developing targeted peptide-based or small-molecule antidepressants that could work through this pathway without ketamine's side effects.

How the study worked

Researchers administered an antidepressant-like dose of ketamine to mice and then used ribosome-bound mRNA footprinting with deep sequencing (RiboSeq) to identify all actively translated mRNAs in the medial prefrontal cortex — creating a genome-wide 'translatome' map. They used Gene Ontology and Gene Set Enrichment Analysis to identify key pathways. They then characterized the VPAC2 receptor's location and function in the cortex, tested a VPAC2 agonist's effects on prefrontal cortical neuron activity in vivo, and assessed whether VPAC2 agonism produced antidepressant-like behavioral effects.

What this study cannot tell us

This was entirely a mouse study, and antidepressant-like behavior in mice does not always predict human clinical responses. The specific VPAC2 agonist used and its dosing were not detailed in the abstract. The study focused on the medial prefrontal cortex, but depression involves multiple brain regions. Long-term effects of VPAC2 agonism and potential side effects were not assessed.

How to read the evidence

This is a preclinical mouse study combining advanced genomic profiling with behavioral and electrophysiological experiments. While the multi-method approach is rigorous, these are animal findings that have not been tested in human clinical trials.

When this study was published

Published in 2025, this is a very recent study representing the cutting edge of ketamine mechanism research and neuropeptide-based antidepressant drug discovery.

The bigger picture

This study bridges two major areas of neuroscience: ketamine research and neuropeptide signaling. Vasoactive intestinal peptide (VIP) has long been known as a brain signaling molecule, but its role in mood regulation was not well established. By showing that VPAC2 activation is both a consequence of ketamine's mechanism and independently sufficient for antidepressant effects, this work positions VIP-VPAC2 as a promising new therapeutic axis — potentially leading to peptide-based antidepressants that are faster-acting than SSRIs but safer than ketamine.

Questions still open

Could a VPAC2 agonist work as a standalone antidepressant in humans without ketamine's dissociative side effects?
Why is VPAC2 expression limited to somatostatin neurons in the prefrontal cortex, and what does this specificity mean for drug targeting?
Would VIP itself or a VIP analog have antidepressant properties if delivered to the brain?

Common questions

What is VIP and why is its receptor important for depression?

VIP (vasoactive intestinal peptide) is a neuropeptide — a small protein used for signaling in the brain. Its receptor VPAC2 was identified in this study as being actively produced in the prefrontal cortex after ketamine treatment. When researchers activated VPAC2 directly with a drug, it produced antidepressant effects in mice, suggesting this neuropeptide pathway could be a new target for treating depression.

How is this different from ketamine itself as a treatment?

Ketamine works as an antidepressant but has significant limitations including dissociative side effects, abuse potential, and the need for clinical supervision. By identifying that one specific downstream effect of ketamine — VPAC2 activation — can independently produce antidepressant effects, this study opens the possibility of developing more targeted drugs that capture ketamine's benefits without its drawbacks.

Read the original research

Genome-Wide Translatome Analysis Following Low-Dose Ketamine to Reveal Novel Targets for Antidepressant Treatment.

Synapse (New York, N.Y.), 79(6), e70033

View on PubMed ↗Publisher’s paper ↗

Citation

Miller, Oliver H; Grabole, Nils; Wells, Isabelle; Bellier, Ludovic; Nassi, Jonathan J; Hall, Benjamin J. (2025). Genome-Wide Translatome Analysis Following Low-Dose Ketamine to Reveal Novel Targets for Antidepressant Treatment.. Synapse (New York, N.Y.), 79(6), e70033. https://doi.org/10.1002/syn.70033